Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with ABVD vs Standard ABVD in Advanced Classical Hodgkin Lymphoma
NCT00654732Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2008
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in classical Hodgkin lymphoma (cHL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2008; status: completed.
02
Drugs
rituximab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT00654732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00654732.